Palvella Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 459.0K | $57.21M | 0.00% | Added+9.2% | 2026-03-31 |
| FidelityFMR | fundamental | 215.8K | $26.90M | 0.00% | Trimmed-6.9% | 2026-03-31 |
| Citadel | multi-strat | 88.2K | $10.99M | 0.01% | Added+14.1% | 2026-03-31 |
| Wellington | fundamental | 34.0K | $4.24M | 0.00% | Added+51.9% | 2026-03-31 |
| RenTech | quant | 18.0K | $2.24M | 0.00% | Trimmed-20.2% | 2026-03-31 |
| TwoSigma | quant | 4.9K | $609.54K | 0.00% | Added+19.6% | 2026-03-31 |
| TRowePrice | fundamental | 402.6K | $50.18K | 0.01% | Added+9742.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -1.17 | — | — |
| 2026-05-07 | -0.93 | -1.20 | -29.29% |
| 2026-03-31 | -0.91 | -1.08 | -18.58% |
| 2025-11-10 | -0.85 | -1.03 | -21.31% |
| 2025-08-14 | -0.77 | -0.86 | -11.98% |
| 2025-05-15 | -1.32 | -0.74 | +43.88% |
| 2025-03-31 | -0.60 | -5.37 | -798.74% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PVLA | -6.61% | -12.57% | +13.17% | +371.20% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -9.58% | -7.74% | +16.62% | +358.58% |